Alebund Pharmaceuticals Plans to Repurchase H Shares for Up to HK$100 Million

SHANGHAI, China, October 20, 2026 — Alebund Pharmaceuticals (Jiangsu) Limited (Stock Code: 09637.HK, "Alebund" or the "Company") today announced that its board of directors (the "Board") has resolved to exercise the general share repurchase mandate granted by the Company's shareholders at the extraordinary general meeting to repurchase H shares of the Company (the "H Shares") in the open market on The Stock Exchange of Hong Kong Limited from time to time, subject to market conditions. Commencing from the date of Board approval, the share repurchase will be conducted within the authorized scope of the mandate for as long as it remains in force, for an aggregate amount of up to HK$100 million (inclusive of brokerage commission, stamp duty, and other related transaction costs). In addition, the Company may undertake further H-share repurchases under the mandate granted by its shareholders, taking into account market conditions. Subject to applicable laws, regulations, and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Company will subsequently cancel and/or hold in treasury any repurchased H Shares, in whole or in part, as the Board deems appropriate.

The proposed share repurchase is intended to safeguard the value of the Company and the interests of its shareholders, and will be funded entirely from the Company's own financial resources, without using any proceeds from its global offering. Having taken into account the trading performance of the H Shares, the Company's business and financial position, its funding needs, and the interests of its shareholders as a whole, the Board considers the share repurchase both necessary and reasonable. The Board believes that the share repurchase will demonstrate the Company's confidence in its business outlook and prospects and will ultimately benefit the Company and create value for its shareholders, and that the Company's existing financial resources allow it to implement the share repurchase while maintaining a solid financial position.

Since its listing in Hong Kong, the Company has made progress across its global R&D pipeline and commercial operations in chronic kidney disease (CKD), including the acceptance of the New Drug Application (NDA) for AP301 in China, the steady advancement of AP306 in global clinical development, regulatory and scientific progress across its broader pipeline, and rapid growth in commercial and licensing revenues. Over the coming year, the Company will continue to advance global multi-regional clinical trials (MRCTs) and regulatory activities in China and the United States for its lead programs, and plans to initiate Phase II clinical trials of AP303 and a Phase I clinical trial of AP308. Alebund remains committed to advancing the clinical development and commercialization of its pipeline to bring better treatment options to patients with kidney disease worldwide and create sustainable long-term value for its shareholders.

About Alebund Pharmaceuticals

Alebund Pharmaceuticals (09637.HK) is a biopharmaceutical company focused on kidney disease and related chronic conditions, aiming to bring better therapies to patients worldwide. It has one of the broadest renal-focused pipelines and an integrated platform spanning R&D, manufacturing and commercialization. Its portfolio comprises seven investigational drug candidates and one commercialized product, Mircera®. Three of the candidates are at the clinical stage: AP301 (Phase III; China pivotal Phase III trial completed and NDA accepted, global MRCT ongoing), AP306 (Phase II) and AP303 (Phase I). The U.S. Food and Drug Administration (FDA) has also cleared the Investigational New Drug (IND) application for AP308. Together they address chronic kidney disease (CKD) and its complications, including hyperphosphatemia, renal anemia, IgA nephropathy, diabetic kidney disease, FSGS and ADPKD. Alebund has built a manufacturing site in Yangzhou, Jiangsu to support the future commercial manufacturing of AP301 and other pipeline products and has obtained a Drug Manufacturing License (Category B) issued by the Jiangsu Provincial Drug Administration. The Company has also established a dedicated nephrology sales team responsible for the commercialization of relevant products in China. For more information, visit www.alebund.com.

礼邦医药拟以不超过 1 亿港元回购公司股份

上海，2026 年 10 月 20 日——礼邦医药（江苏）股份有限公司（股票代码：09637.HK，“礼邦医药”或“公司”）今日宣布，公司董事会已决议行使股东于临时股东会上授予董事会的 H 股回购一般性授权（“回购授权”），拟自董事会审议通过之日起，在回购授权持续有效且符合该授权范围的期间内，视市场情况不时于香港联合交易所有限公司公开市场回购公司 H 股，总金额不超过 1 亿港元（含经纪佣金、印花税等相关交易费用）。此外，公司或将视市场情况，在股东会授予的回购授权范围内进一步回购 H 股。公司后续将根据董事会认为适当的安排，在符合适用法律法规及《上市规则》的前提下，将所回购的 H 股全部或部分予以注销及/或持作库存股份。

本次股份回购旨在维护公司价值及股东权益，所需资金全部来自公司自有资金，不使用公司全球发售所得募集资金。董事会在综合考虑 H 股交易表现、公司业务及财务状况、资金需求及股东整体利益等因素后，认为本次股份回购具有必要性和合理性。董事会相信，本次股份回购将彰显公司对自身业务展望及发展前景的信心，最终将令公司受益并为股东创造价值；同时，公司现有的财务资源能够支持公司在维持稳健财务状况的同时实施本次股份回购。

自公司港股上市以来，公司围绕慢性肾脏病（CKD）领域的全球研发与商业化布局持续推进，AP301 中国新药上市申请（NDA）获正式受理，AP306 全球临床开发稳步推进，后续创新管线相继取得重要监管与学术进展，商业化与对外授权收入亦实现快速增长。展望未来一年，公司将继续推进主要管线的全球多区域临床试验及中美注册相关工作，并计划启动 AP303 II 期及 AP308 I 期临床试验。礼邦医药将持续推动创新成果的临床转化与商业化，致力于为全球肾脏病患者提供更优的治疗选择，并为股东创造长期可持续的价值。

关于礼邦医药

礼邦医药（09637.HK）是一家专注于肾脏疾病及相关慢性病领域的生物医药公司。围绕慢性肾脏病（CKD）不同阶段及其并发症的临床需求，公司构建了肾病适应症覆盖广泛的创新产品组合，并形成涵盖研发、生产及商业化的一体化平台，致力于为全球肾脏疾病患者带来更优的治疗方案。目前，公司已拥有 7 款在研候选产品及 1 款商业化产品（美信罗®），其中 AP301、AP306 及 AP303 三款在研产品已进入临床阶段，分别处于临床 III 期、II 期及 I 期，其中 AP301 的中国关键 III 期临床试验已完成且新药上市申请已获受理，全球多区域临床试验（MRCT）正在进行。AP308 已获美国食品药品监督管理局（FDA）的新药临床试验申请（IND）许可。整体产品组合覆盖慢性肾脏病及其并发症的多个适应症，包括高磷血症、肾性贫血、IgA 肾病、糖尿病肾病、局灶节段性肾小球硬化及常染色体显性多囊肾病。公司已在江苏扬州建成生产基地，以支持 AP301 等管线产品未来的商业化

生产，并已取得江苏省药品监督管理局颁发的《药品生产许可证》（B 类）；同时，公司已组建肾科专科销售团队，负责相关产品在中国的商业化推广。更多信息，请访问：www.alebund.com。